Review Article | Published:

Inflammasomes in the gastrointestinal tract: infection, cancer and gut microbiota homeostasis

Nature Reviews Gastroenterology & Hepatologyvolume 15pages721737 (2018) | Download Citation


Inflammasome signalling is an emerging pillar of innate immunity and has a central role in the regulation of gastrointestinal health and disease. Activation of the inflammasome complex mediates both the release of the pro-inflammatory cytokines IL-1β and IL-18 and the execution of a form of inflammatory cell death known as pyroptosis. In most cases, these mediators of inflammation provide protection against bacterial, viral and protozoal infections. However, unchecked inflammasome activities perpetuate chronic inflammation, which underpins the molecular and pathophysiological basis of gastritis, IBD, upper and lower gastrointestinal cancer, nonalcoholic fatty liver disease and obesity. Studies have also highlighted an inflammasome signature in the maintenance of gut microbiota and gut–brain homeostasis. Harnessing the immunomodulatory properties of the inflammasome could transform clinical practice in the treatment of acute and chronic gastrointestinal and extragastrointestinal diseases. This Review presents an overview of inflammasome biology in gastrointestinal health and disease and describes the value of experimental and pharmacological intervention in the treatment of inflammasome-associated clinical manifestations.

Key points

  • Inflammasomes are expressed in both immune and non-immune cells, contributing to their functional ties to infection, IBD, cancer, autoinflammation and autoimmune conditions.

  • Inflammasome sensors function by recognizing and responding to a pathogen (lipopolysaccharide, microbial DNA or bacterial flagellin) or to a danger signal (ion flux, self-DNA or ATP).

  • Inflammasomes control the magnitude of inflammation and cell death in response to pathogen-associated molecular patterns or danger-associated molecular patterns, which, in part, determines a protective or detrimental outcome in the host.

  • Experimental and pharmacological interventions have yielded success in the treatment of inflammasome-mediated disorders, such as autoinflammatory enterocolitis.

  • The inflammasome–gut microbiota axis and its relevance to health and disease are influenced by genetic, environmental and experimental factors.

  • The deep and complex relationship between inflammasomes, pathogens and the microbiota provides an exciting platform for basic and clinical research with which to understand health and disease.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121–141 (2014).

  2. 2.

    Martinon, F., Burns, K. & Tschopp, J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell 10, 417–426 (2002).

  3. 3.

    Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821–832 (2010).

  4. 4.

    Lamkanfi, M. & Dixit, V. M. Mechanisms and functions of inflammasomes. Cell 157, 1013–1022 (2014).

  5. 5.

    Man, S. M. & Kanneganti, T. D. Converging roles of caspases in inflammasome activation, cell death and innate immunity. Nat. Rev. Immunol. 16, 7–21 (2016).

  6. 6.

    Rathinam, V. A. & Fitzgerald, K. A. Inflammasome complexes: emerging mechanisms and effector functions. Cell 165, 792–800 (2016).

  7. 7.

    Broz, P. & Dixit, V. M. Inflammasomes: mechanism of assembly, regulation and signalling. Nat. Rev. Immunol. 16, 407–420 (2016).

  8. 8.

    Conos, S. A., Lawlor, K. E., Vaux, D. L., Vince, J. E. & Lindqvist, L. M. Cell death is not essential for caspase-1-mediated interleukin-1beta activation and secretion. Cell Death Differ. 23, 1827–1838 (2016).

  9. 9.

    Evavold, C. L. et al. The pore-forming protein gasdermin D regulates interleukin-1 secretion from living macrophages. Immunity 48, 35–44 (2018).

  10. 10.

    Heilig, R. et al. The Gasdermin-D pore acts as a conduit for IL-1beta secretion in mice. Eur. J. Immunol. 48, 584–592 (2018).

  11. 11.

    Szabo, G. & Petrasek, J. Inflammasome activation and function in liver disease. Nat. Rev. Gastroenterol. Hepatol. 12, 387–400 (2015).

  12. 12.

    Guo, H., Callaway, J. B. & Ting, J. P. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med. 21, 677–687 (2015).

  13. 13.

    Levy, M., Kolodziejczyk, A. A., Thaiss, C. A. & Elinav, E. Dysbiosis and the immune system. Nat. Rev. Immunol. 17, 219–232 (2017).

  14. 14.

    Man, S. M. & Kanneganti, T. D. Regulation of inflammasome activation. Immunol. Rev. 265, 6–21 (2015).

  15. 15.

    Latz, E., Xiao, T. S. & Stutz, A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13, 397–411 (2013).

  16. 16.

    Kayagaki, N. et al. Non-canonical inflammasome activation targets caspase-11. Nature 479, 117–121 (2011). This study describes the existence of a non-canonical inflammasome.

  17. 17.

    Liston, A. & Masters, S. L. Homeostasis-altering molecular processes as mechanisms of inflammasome activation. Nat. Rev. Immunol. 17, 208–214 (2017).

  18. 18.

    Hornung, V. et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 458, 514–518 (2009).

  19. 19.

    Fernandes-Alnemri, T., Yu, J. W., Datta, P., Wu, J. & Alnemri, E. S. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458, 509–513 (2009).

  20. 20.

    Burckstummer, T. et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nat. Immunol. 10, 266–272 (2009).

  21. 21.

    Roberts, T. L. et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 323, 1057–1060 (2009). References 18–21 show that AIM2 is a cytosolic inflammasome sensor of double-stranded DNA.

  22. 22.

    Shi, J. et al. Inflammatory caspases are innate immune receptors for intracellular LPS. Nature 514, 187–192 (2014).

  23. 23.

    Mariathasan, S. et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 430, 213–218 (2004). This study provides the first genetic evidence for the existence of an NLRC4 inflammasome (previously known as the ICE-protease activating factor (IPAF) inflammasome).

  24. 24.

    Franchi, L. et al. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages. Nat. Immunol. 7, 576–582 (2006).

  25. 25.

    Miao, E. A. et al. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat. Immunol. 7, 569–575 (2006).

  26. 26.

    Miao, E. A. et al. Innate immune detection of the type III secretion apparatus through the NLRC4 inflammasome. Proc. Natl Acad. Sci. USA 107, 3076–3080 (2010).

  27. 27.

    Amer, A. et al. Regulation of Legionella phagosome maturation and infection through flagellin and host Ipaf. J. Biol. Chem. 281, 35217–35223 (2006).

  28. 28.

    Zhao, Y. et al. The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus. Nature 477, 596–600 (2011).

  29. 29.

    Kortmann, J., Brubaker, S. W. & Monack, D. M. Cutting edge: inflammasome activation in primary human macrophages is dependent on flagellin. J. Immunol. 195, 815–819 (2015).

  30. 30.

    Reyes Ruiz, V. M. et al. Broad detection of bacterial type III secretion system and flagellin proteins by the human NAIP/NLRC4 inflammasome. Proc. Natl Acad. Sci. USA 114, 13242–13247 (2017).

  31. 31.

    Kofoed, E. M. & Vance, R. E. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 477, 592–595 (2011).

  32. 32.

    Rayamajhi, M., Zak, D. E., Chavarria-Smith, J., Vance, R. E. & Miao, E. A. Cutting edge: mouse NAIP1 detects the type III secretion system needle protein. J. Immunol. 191, 3986–3989 (2013).

  33. 33.

    Rauch, I. et al. NAIP proteins are required for cytosolic detection of specific bacterial ligands in vivo. J. Exp. Med. 213, 657–665 (2016).

  34. 34.

    Zhao, Y. et al. Genetic functions of the NAIP family of inflammasome receptors for bacterial ligands in mice. J. Exp. Med. 213, 647–656 (2016).

  35. 35.

    Halff, E. F. et al. Formation and structure of a NAIP5-NLRC4 inflammasome induced by direct interactions with conserved N and C-terminal regions of flagellin. J. Biol. Chem. 287, 38460–38472 (2012).

  36. 36.

    Hu, Z. et al. Structural and biochemical basis for induced self-propagation of NLRC4. Science 350, 399–404 (2015).

  37. 37.

    D’Osualdo, A. et al. CARD8 and NLRP1 undergo autoproteolytic processing through a ZU5-like domain. PloS one 6, e27396 (2011).

  38. 38.

    Frew, B. C., Joag, V. R. & Mogridge, J. Proteolytic processing of Nlrp1b is required for inflammasome activity. PLoS Pathog. 8, e1002659 (2012).

  39. 39.

    Finger, J. N. et al. Autolytic proteolysis within the function to find domain (FIIND) is required for NLRP1 inflammasome activity. J. Biol. Chem. 287, 25030–25037 (2012).

  40. 40.

    Chavarria-Smith, J., Mitchell, P. S., Ho, A. M., Daugherty, M. D. & Vance, R. E. Functional and evolutionary analyses identify proteolysis as a general mechanism for NLRP1 inflammasome activation. PLoS Pathog. 12, e1006052 (2016).

  41. 41.

    Levinsohn, J. L. et al. Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome. PLoS Pathog. 8, e1002638 (2012).

  42. 42.

    Perregaux, D. & Gabel, C. A. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J. Biol. Chem. 269, 15195–15203 (1994).

  43. 43.

    Muñoz-Planillo, R. et al. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38, 1142–1153 (2013).

  44. 44.

    Petrilli, V. et al. Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ. 14, 1583–1589 (2007).

  45. 45.

    Hornung, V. et al. Silica crystals and aluminum salts mediate NALP-3 inflammasome activation via phagosomal destabilization. Nat. Immunol. 9, 847–856 (2008).

  46. 46.

    Zhou, R., Yazdi, A. S., Menu, P. & Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature 469, 221–225 (2011).

  47. 47.

    Shimada, K. et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36, 401–414 (2012).

  48. 48.

    Iyer, S. S. et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity 39, 311–323 (2013).

  49. 49.

    Groß, C. J. et al. K+ efflux-independent NLRP3 Inflammasome activation by small molecules targeting mitochondria. Immunity 45, 761–773 (2016).

  50. 50.

    Murakami, T. et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc. Natl Acad. Sci. USA 109, 11282–11287 (2012).

  51. 51.

    Xu, H. et al. Innate immune sensing of bacterial modifications of Rho GTPases by the Pyrin inflammasome. Nature 513, 237–241 (2014).

  52. 52.

    Gavrilin, M. A. et al. Activation of the pyrin inflammasome by intracellular Burkholderia cenocepacia. J. Immunol. 188, 3469–3477 (2012).

  53. 53.

    Masters, S. L. et al. Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation. Sci. Transl Med. 8, 332ra345 (2016).

  54. 54.

    Park, Y. H., Wood, G., Kastner, D. L. & Chae, J. J. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat. Immunol. 17, 914–921 (2016).

  55. 55.

    Broz, P. et al. Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J. Exp. Med. 207, 1745–1755 (2010).

  56. 56.

    Broz, P., von Moltke, J., Jones, J. W., Vance, R. E. & Monack, D. M. Differential requirement for Caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. Cell Host Microbe 8, 471–483 (2010).

  57. 57.

    Fernandes-Alnemri, T. et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 14, 1590–1604 (2007).

  58. 58.

    Man, S. M. et al. Salmonella infection induces recruitment of caspase-8 to the inflammasome to modulate IL-1beta production. J. Immunol. 191, 5239–5246 (2013).

  59. 59.

    Franklin, B. S. et al. The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation. Nat. Immunol. 15, 727–737 (2014).

  60. 60.

    Lu, A. et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell 156, 1193–1206 (2014).

  61. 61.

    Cai, X. et al. Prion-like polymerization underlies signal transduction in antiviral immune defense and inflammasome activation. Cell 156, 1207–1222 (2014).

  62. 62.

    Baroja-Mazo, A. et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat. Immunol. 15, 738–748 (2014).

  63. 63.

    Man, S. M., Karki, R. & Kanneganti, T. D. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol. Rev. 277, 61–75 (2017).

  64. 64.

    Poyet, J. L. et al. Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1. J. Biol. Chem. 276, 28309–28313 (2001).

  65. 65.

    Van Opdenbosch, N. et al. Activation of the NLRP1b inflammasome independently of ASC-mediated caspase-1 autoproteolysis and speck formation. Nat. Commun. 5, 3209 (2014).

  66. 66.

    Guey, B., Bodnar, M., Manie, S. N., Tardivel, A. & Petrilli, V. Caspase-1 autoproteolysis is differentially required for NLRP1b and NLRP3 inflammasome function. Proc. Natl Acad. Sci. USA 111, 17254–17259 (2014).

  67. 67.

    Kostura, M. J. et al. Identification of a monocyte specific pre-interleukin 1 beta convertase activity. Proc. Natl Acad. Sci. USA 86, 5227–5231 (1989).

  68. 68.

    Black, R. A., Kronheim, S. R. & Sleath, P. R. Activation of interleukin-1 beta by a co-induced protease. FEBS Lett. 247, 386–390 (1989).

  69. 69.

    Thornberry, N. A. et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 356, 768–774 (1992).

  70. 70.

    Ghayur, T. et al. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production. Nature 386, 619–623 (1997).

  71. 71.

    Vande Walle, L. & Lamkanfi, M. Pyroptosis. Curr. Biol. 26, R568–R572 (2016).

  72. 72.

    Aglietti, R. A. & Dueber, E. C. Recent insights into the molecular mechanisms underlying pyroptosis and gasdermin family functions. Trends Immunol. 38, 261–271 (2017).

  73. 73.

    Kayagaki, N. et al. Caspase-11 cleaves gasdermin D for non-canonical inflammasome signaling. Nature 526, 666–671 (2015).

  74. 74.

    Shi, J. et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526, 660–665 (2015). References 73 and 74 demonstrate that gasdermin D is a substrate of inflammatory caspases that upon cleavage converts to a pro-pyroptotic executor mediating cell lysis.

  75. 75.

    He, W. T. et al. Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion. Cell Res. 25, 1285–1298 (2015).

  76. 76.

    Ding, J. et al. Pore-forming activity and structural autoinhibition of the gasdermin family. Nature 535, 111–116 (2016).

  77. 77.

    Aglietti, R. A. et al. GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes. Proc. Natl Acad. Sci. USA 113, 7858–7863 (2016).

  78. 78.

    Liu, X. et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 535, 153–158 (2016).

  79. 79.

    Sborgi, L. et al. GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death. EMBO J. 35, 1766–1778 (2016).

  80. 80.

    Chen, X. et al. Pyroptosis is driven by non-selective gasdermin-D pore and its morphology is different from MLKL channel-mediated necroptosis. Cell Res. 26, 1007–1020 (2016).

  81. 81.

    Joosten, L. A., Netea, M. G. & Dinarello, C. A. Interleukin-1beta in innate inflammation, autophagy and immunity. Semin. Immunol. 25, 416–424 (2013).

  82. 82.

    Dinarello, C. A., Novick, D., Kim, S. & Kaplanski, G. Interleukin-18 and IL-18 binding protein. Front. Immunol. 4, 289 (2013).

  83. 83.

    Navaneethan, U. & Giannella, R. A. Mechanisms of infectious diarrhea. Nat. Clin. Pract. Gastroenterol. Hepatol. 5, 637–647 (2008).

  84. 84.

    Miao, E. A. et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat. Immunol. 11, 1136–1142 (2010).

  85. 85.

    Franchi, L. et al. NLRC4-driven production of IL-1beta discriminates between pathogenic and commensal bacteria and promotes host intestinal defense. Nat. Immunol. 13, 449–456 (2012).

  86. 86.

    Kupz, A. et al. NLRC4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8(+) T cells. Nat. Immunol. 13, 162–169 (2012).

  87. 87.

    Man S. M. et al. Inflammasome activation causes dual recruitment of NLRC4 and NLRP3 to the same macromolecular complex. Proc. Natl. Acad. Sci. USA 111, 7403–7408 (2014).

  88. 88.

    Suzuki, S. et al. Shigella type III secretion protein MxiI is recognized by Naip2 to induce Nlrc4 inflammasome activation independently of Pkcdelta. PLoS Pathog. 10, e1003926 (2014).

  89. 89.

    Suzuki, S. et al. Shigella IpaH7.8 E3 ubiquitin ligase targets glomulin and activates inflammasomes to demolish macrophages. Proc. Natl Acad. Sci. USA 111, E4254–E4263 (2014).

  90. 90.

    Wu, J., Fernandes-Alnemri, T. & Alnemri, E. S. Involvement of the AIM2, NLRC4, and NLRP3 inflammasomes in caspase-1 activation by Listeria monocytogenes. J. Clin. Immunol. 30, 693–702 (2010).

  91. 91.

    Liu, Z. et al. Role of inflammasomes in host defense against Citrobacter rodentium infection. J. Biol. Chem. 287, 16955–16964 (2012).

  92. 92.

    Nordlander, S., Pott, J. & Maloy, K. J. NLRC4 expression in intestinal epithelial cells mediates protection against an enteric pathogen. Mucosal Immunol. 7, 775–785 (2014).

  93. 93.

    Sellin, M. E. et al. Epithelium-Intrinsic NAIP/NLRC4 inflammasome drives infected enterocyte expulsion to restrict Salmonella replication in the intestinal mucosa. Cell Host Microbe 16, 237–248 (2014).

  94. 94.

    Rauch, I. et al. NAIP-NLRC4 inflammasomes coordinate intestinal epithelial cell expulsion with eicosanoid and IL-18 release via activation of caspase-1 and -8. Immunity 46, 649–659 (2017).

  95. 95.

    Filardy, A. A., He, J., Bennink, J., Yewdell, J. & Kelsall, B. L. Posttranscriptional control of NLRP3 inflammasome activation in colonic macrophages. Mucosal Immunol. 9, 850–858 (2016).

  96. 96.

    Ngo, C. C. & Man, S. M. Mechanisms and functions of guanylate-binding proteins and related interferon-inducible GTPases: roles in intracellular lysis of pathogens. Cell. Microbiol. 19, e12791 (2017).

  97. 97.

    Kayagaki, N. et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science 341, 1246–1249 (2013).

  98. 98.

    Hagar, J. A., Powell, D. A., Aachoui, Y., Ernst, R. K. & Miao, E. A. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Science 341, 1250–1253 (2013).

  99. 99.

    Aachoui, Y. et al. Caspase-11 protects against bacteria that escape the vacuole. Science 339, 975–978 (2013).

  100. 100.

    Aachoui, Y. et al. Canonical inflammasomes drive IFN-gamma to prime caspase-11 in defense against a cytosol-invasive bacterium. Cell Host Microbe 18, 320–332 (2015).

  101. 101.

    Kaparakis-Liaskos, M. & Ferrero, R. L. Immune modulation by bacterial outer membrane vesicles. Nat. Rev. Immunol. 15, 375–387 (2015).

  102. 102.

    Vanaja, S. K. et al. Bacterial outer membrane vesicles mediate cytosolic localization of LPS and Caspase-11 activation. Cell 165, 1106–1119 (2016).

  103. 103.

    Jorgensen, I., Zhang, Y., Krantz, B. A. & Miao, E. A. Pyroptosis triggers pore-induced intracellular traps (PITs) that capture bacteria and lead to their clearance by efferocytosis. J. Exp. Med. 213, 2113–2128 (2016).

  104. 104.

    Knodler, L. A. et al. Noncanonical inflammasome activation of caspase-4/caspase-11 mediates epithelial defenses against enteric bacterial pathogens. Cell Host Microbe 16, 249–256 (2014). References 93, 94 and 104 highlight an expulsion mechanism induced by the inflammasome to remove an entire infected host cell from the intestinal epithelium.

  105. 105.

    Man, S. M. et al. Actin polymerization as a key innate immune effector mechanism to control Salmonella infection. Proc. Natl Acad. Sci. USA 111, 17588–17593 (2014).

  106. 106.

    Chen, K. W. et al. The neutrophil NLRC4 inflammasome selectively promotes IL-1beta maturation without pyroptosis during acute Salmonella challenge. Cell Rep. 8, 570–582 (2014).

  107. 107.

    O’Connor, A., O’Morain, C. A. & Ford, A. C. Population screening and treatment of Helicobacter pylori infection. Nat. Rev. Gastroenterol. Hepatol. 14, 230–240 (2017).

  108. 108.

    Matusiak, M. et al. Flagellin-induced NLRC4 phosphorylation primes the inflammasome for activation by NAIP5. Proc. Natl Acad. Sci. USA 112, 1541–1546 (2015).

  109. 109.

    Koch, K. N. et al. Helicobacter urease-induced activation of the TLR2/NLRP3/IL-18 axis protects against asthma. J. Clin. Invest. 125, 3297–3302 (2015).

  110. 110.

    Perez-Figueroa, E. et al. Activation of NLRP3 inflammasome in human neutrophils by Helicobacter pylori infection. Innate Immun. 22, 103–112 (2016).

  111. 111.

    Li, X. et al. Helicobacter pylori induces IL-1beta and IL-18 production in human monocytic cell line through activation of NLRP3 inflammasome via ROS signaling pathway. Pathog. Dis. 73, ftu024 (2015).

  112. 112.

    Semper, R. P. et al. Helicobacter pylori-induced IL-1beta secretion in innate immune cells is regulated by the NLRP3 inflammasome and requires the cag pathogenicity island. J. Immunol. 193, 3566–3576 (2014).

  113. 113.

    Kim, D. J., Park, J. H., Franchi, L., Backert, S. & Nunez, G. The Cag pathogenicity island and interaction between TLR2/NOD2 and NLRP3 regulate IL-1beta production in Helicobacter pylori infected dendritic cells. Eur. J. Immunol. 43, 2650–2658 (2013).

  114. 114.

    Tu, S. et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14, 408–419 (2008).

  115. 115.

    Castano-Rodriguez, N., Kaakoush, N. O., Goh, K. L., Fock, K. M. & Mitchell, H. M. The NOD-like receptor signalling pathway in Helicobacter pylori infection and related gastric cancer: a case-control study and gene expression analyses. PLOS ONE 9, e98899 (2014).

  116. 116.

    Li, S. et al. MiR-22 sustains NLRP3 expression and attenuates H. pylori-induced gastric carcinogenesis. Oncogene 37, 884–896 (2018).

  117. 117.

    Martin, J. S., Monaghan, T. M. & Wilcox, M. H. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat. Rev. Gastroenterol. Hepatol. 13, 206–216 (2016).

  118. 118.

    Ng, J. et al. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology 139, 542–552 (2010).

  119. 119.

    Van Gorp, H. et al. Familial Mediterranean fever mutations lift the obligatory requirement for microtubules in Pyrin inflammasome activation. Proc. Natl Acad. Sci. USA 113, 14384–14389 (2016).

  120. 120.

    Gao, W., Yang, J., Liu, W., Wang, Y. & Shao, F. Site-specific phosphorylation and microtubule dynamics control Pyrin inflammasome activation. Proc. Natl Acad. Sci. USA 113, E4857–E4866 (2016).

  121. 121.

    Seo, S. U. et al. Distinct commensals induce interleukin-1beta via NLRP3 inflammasome in inflammatory monocytes to promote intestinal inflammation in response to injury. Immunity 42, 744–755 (2015).

  122. 122.

    Mariathasan, S. et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440, 228–232 (2006).

  123. 123.

    Munoz-Planillo, R., Franchi, L., Miller, L. S. & Nunez, G. A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureus-induced activation of the Nlrp3 inflammasome. J. Immunol. 183, 3942–3948 (2009).

  124. 124.

    Kim, S. et al. Listeria monocytogenes is sensed by the NLRP3 and AIM2 inflammasome. Eur. J. Immunol. 40, 1545–1551 (2010).

  125. 125.

    Sauer, J. D. et al. Listeria monocytogenes triggers AIM2-mediated pyroptosis upon infrequent bacteriolysis in the macrophage cytosol. Cell Host Microbe 7, 412–419 (2010).

  126. 126.

    Warren, S. E. et al. Cutting edge: Cytosolic bacterial DNA activates the inflammasome via Aim2. J. Immunol. 185, 818–821 (2010).

  127. 127.

    Tsuchiya, K. et al. Involvement of absent in melanoma 2 in inflammasome activation in macrophages infected with Listeria monocytogenes. J. Immunol. 185, 1186–1195 (2010).

  128. 128.

    Meixenberger, K. et al. Listeria monocytogenes-infected human peripheral blood mononuclear cells produce IL-1beta, depending on listeriolysin O and NLRP3. J. Immunol. 184, 922–930 (2010).

  129. 129.

    Khare, S. et al. An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. Immunity 36, 464–476 (2012).

  130. 130.

    Akhter, A. et al. Caspase-11 promotes the fusion of phagosomes harboring pathogenic bacteria with lysosomes by modulating actin polymerization. Immunity 37, 35–47 (2012).

  131. 131.

    Thurston, T. L. et al. Growth inhibition of cytosolic Salmonella by caspase-1 and caspase-11 precedes host cell death. Nat. Commun. 7, 13292 (2016).

  132. 132.

    Sokolovska, A. et al. Activation of caspase-1 by the NLRP3 inflammasome regulates the NADPH oxidase NOX2 to control phagosome function. Nat. Immunol. 14, 543–553 (2013).

  133. 133.

    Anand, P. K. et al. NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens. Nature 488, 389–393 (2012).

  134. 134.

    Zaki, M. H., Man, S. M., Vogel, P., Lamkanfi, M. & Kanneganti, T. D. Salmonella exploits NLRP12-dependent innate immune signaling to suppress host defenses during infection. Proc. Natl Acad. Sci. USA 111, 385–390 (2014).

  135. 135.

    Allen, I. C. et al. Characterization of NLRP12 during the in vivo host immune response to Klebsiella pneumoniae and Mycobacterium tuberculosis. PLOS ONE 8, e60842 (2013).

  136. 136.

    Silveira, T. N. et al. NLRP12 negatively regulates proinflammatory cytokine production and host defense against Brucella abortus. Eur. J. Immunol. 47, 51–59 (2017).

  137. 137.

    Wlodarska, M. et al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell 156, 1045–1059 (2014).

  138. 138.

    Vladimer, G. I. et al. The NLRP12 inflammasome recognizes Yersinia pestis. Immunity 37, 96–107 (2012).

  139. 139.

    Zamoshnikova, A. et al. NLRP12 is a neutrophil-specific, negative regulator of in vitro cell migration but does not modulate LPS- or infection-induced NF-kappaB or ERK signalling. Immunobiology 221, 341–346 (2016).

  140. 140.

    Ulland, T. K. et al. Nlrp12 mutation causes C57BL/6J strain-specific defect in neutrophil recruitment. Nat. Commun. 7, 13180 (2016).

  141. 141.

    Sarkar, A. et al. Caspase-1 regulates Escherichia coli sepsis and splenic B cell apoptosis independently of interleukin-1beta and interleukin-18. Am. J. Respir. Crit. Care Med. 174, 1003–1010 (2006).

  142. 142.

    Wang, S. et al. Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE. Cell 92, 501–509 (1998).

  143. 143.

    Li, P. et al. Mice deficient in IL-1 beta-converting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80, 401–411 (1995).

  144. 144.

    Man, S. M. et al. Differential roles of caspase-1 and caspase-11 in infection and inflammation. Sci. Rep. 7, 45126 (2017).

  145. 145.

    Lee, S. et al. NLRP3 inflammasome deficiency protects against microbial sepsis via increased lipoxin B4 synthesis. Am. J. Respir. Crit. Care Med. 196, 713–726 (2017).

  146. 146.

    Jin, L., Batra, S. & Jeyaseelan, S. Deletion of Nlrp3 augments survival during polymicrobial sepsis by decreasing autophagy and enhancing phagocytosis. J. Immunol. 198, 1253–1262 (2017).

  147. 147.

    Hao, H. et al. Farnesoid X receptor regulation of the NLRP3 Inflammasome underlies cholestasis-associated sepsis. Cell. Metab. 25, 856–867 (2017).

  148. 148.

    Guo, C. et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity 45, 802–816 (2016).

  149. 149.

    von Moltke, J. et al. Rapid induction of inflammatory lipid mediators by the inflammasome in vivo. Nature 490, 107–111 (2012).

  150. 150.

    Ayres, J. S., Trinidad, N. J. & Vance, R. E. Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat. Med. 18, 799–806 (2012).

  151. 151.

    Schieber, A. M. et al. Disease tolerance mediated by microbiome E. coli involves inflammasome and IGF-1 signaling. Science 350, 558–563 (2015).

  152. 152.

    Christensen, M. L. Human viral gastroenteritis. Clin. Microbiol. Rev. 2, 51–89 (1989).

  153. 153.

    Shayakhmetov, D. M., Li, Z. Y., Ni, S. & Lieber, A. Interference with the IL-1-signaling pathway improves the toxicity profile of systemically applied adenovirus vectors. J. Immunol. 174, 7310–7319 (2005).

  154. 154.

    Muruve, D. A. et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452, 103–107 (2008).

  155. 155.

    Barlan, A. U., Griffin, T. M., McGuire, K. A. & Wiethoff, C. M. Adenovirus membrane penetration activates the NLRP3 inflammasome. J. Virol. 85, 146–155 (2011).

  156. 156.

    Teigler, J. E., Kagan, J. C. & Barouch, D. H. Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity. J. Virol. 88, 10354–10363 (2014).

  157. 157.

    Solomon, T. et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 10, 778–790 (2010).

  158. 158.

    Wang, H. et al. Reciprocal regulation between Enterovirus 71 and the NLRP3 inflammasome. Cell Rep. 12, 42–48 (2015).

  159. 159.

    Li, Z. et al. Interleukin-18 protects mice from Enterovirus 71 infection. Cytokine 96, 132–137 (2017).

  160. 160.

    Operario, D. J. et al. Etiology of severe acute watery diarrhea in children in the global Rotavirus Surveillance Network using quantitative polymerase chain reaction. J. Infect. Dis. 216, 220–227 (2017).

  161. 161.

    Zhu, S. et al. Nlrp9b inflammasome restricts rotavirus infection in intestinal epithelial cells. Nature 546, 667–670 (2017). This study reports the existence of an NLRP9b inflammasome complex, which is expressed specifically in mouse intestinal cells and mediates cytosolic recognition of rotavirus.

  162. 162.

    Zhang, B. et al. Prevention and cure of rotavirus infection via TLR5/NLRC4-mediated production of IL-22 and IL-18. Science 346, 861–865 (2014).

  163. 163.

    Elinav, E. et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145, 745–757 (2011).

  164. 164.

    Kempster, S. L. et al. Developmental control of the Nlrp6 inflammasome and a substrate, IL-18, in mammalian intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 300, G253–G263 (2011).

  165. 165.

    Wang, P. et al. Nlrp6 regulates intestinal antiviral innate immunity. Science 350, 826–830 (2015).

  166. 166.

    Fletcher, S. M., Stark, D., Harkness, J. & Ellis, J. Enteric protozoa in the developed world: a public health perspective. Clin. Microbiol. Rev. 25, 420–449 (2012).

  167. 167.

    Zamboni, D. S. & Lima-Junior, D. S. Inflammasomes in host response to protozoan parasites. Immunol. Rev. 265, 156–171 (2015).

  168. 168.

    Tanyuksel, M. & Petri, W. A. Jr. Laboratory diagnosis of amebiasis. Clin. Microbiol. Rev. 16, 713–729 (2003).

  169. 169.

    Mortimer, L., Moreau, F., Cornick, S. & Chadee, K. Gal-lectin-dependent contact activates the inflammasome by invasive Entamoeba histolytica. Mucosal Immunol. 7, 829–841 (2014).

  170. 170.

    Marie, C., Verkerke, H. P., Theodorescu, D. & Petri, W. A. A whole-genome RNAi screen uncovers a novel role for human potassium channels in cell killing by the parasite Entamoeba histolytica. Sci. Rep. 5, 13613 (2015).

  171. 171.

    Mortimer, L., Moreau, F., Cornick, S. & Chadee, K. The NLRP3 Inflammasome is a pathogen sensor for invasive Entamoeba histolytica via activation of alpha5beta1 integrin at the macrophage-amebae intercellular junction. PLoS Pathog. 11, e1004887 (2015).

  172. 172.

    Zhang, Z. et al. Entamoeba histolytica cysteine proteinases with interleukin-1 beta converting enzyme (ICE) activity cause intestinal inflammation and tissue damage in amoebiasis. Mol. Microbiol. 37, 542–548 (2000).

  173. 173.

    Que, X. et al. A surface amebic cysteine proteinase inactivates interleukin-18. Infect. Immun. 71, 1274–1280 (2003).

  174. 174.

    Chudnovskiy, A. et al. Host-protozoan interactions protect from mucosal infections through activation of the inflammasome. Cell 167, 444–456 (2016).

  175. 175.

    Mathur, A., Hayward, J. A. & Man, S. M. Molecular mechanisms of inflammasome signaling. J. Leukoc. Biol. 103, 233–257 (2018).

  176. 176.

    Zmora, N., Levy, M., Pevsner-Fishcer, M. & Elinav, E. Inflammasomes and intestinal inflammation. Mucosal Immunol. 10, 865–883 (2017).

  177. 177.

    Man, S. M., Kaakoush, N. O. & Mitchell, H. M. The role of bacteria and pattern-recognition receptors in Crohn’s disease. Nat. Rev. Gastroenterol. Hepatol. 8, 152–168 (2011).

  178. 178.

    Villani, A. C. et al. Common variants in the NLRP3 region contribute to Crohn’s disease susceptibility. Nat. Genet. 41, 71–76 (2009).

  179. 179.

    Lewis, G. J. et al. Genetic association between NLRP3 variants and Crohn’s disease does not replicate in a large UK panel. Inflamm. Bowel Dis. 17, 1387–1391 (2011).

  180. 180.

    Ungerback, J. et al. Genetic variation and alterations of genes involved in NFkappaB/TNFAIP3- and NLRP3-inflammasome signaling affect susceptibility and outcome of colorectal cancer. Carcinogenesis 33, 2126–2134 (2012).

  181. 181.

    Liu, R. et al. Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components. Oncotarget 6, 33456–33469 (2015).

  182. 182.

    Karki, R., Man, S. M. & Kanneganti, T. D. Inflammasomes and cancer. Cancer Immunol. Res. 5, 94–99 (2017).

  183. 183.

    Zaki, M. H., Vogel, P., Body-Malapel, M., Lamkanfi, M. & Kanneganti, T. D. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J. Immunol. 185, 4912–4920 (2010).

  184. 184.

    Allen, I. C. et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J. Exp. Med. 207, 1045–1056 (2010).

  185. 185.

    Zaki, M. H. et al. The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32, 379–391 (2010).

  186. 186.

    Hirota, S. A. et al. NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm. Bowel Dis. 17, 1359–1372 (2011).

  187. 187.

    Dupaul-Chicoine, J. et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity 32, 367–378 (2010).

  188. 188.

    Blazejewski, A. J. et al. Microbiota normalization reveals that canonical caspase-1 activation exacerbates chemically induced intestinal inflammation. Cell Rep. 19, 2319–2330 (2017).

  189. 189.

    Gulbransen, B. D. et al. Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis. Nat. Med. 18, 600–604 (2012).

  190. 190.

    Neudecker, V. et al. Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome. J. Exp. Med. 214, 1737–1752 (2017).

  191. 191.

    Bauer, C. et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59, 1192–1199 (2010).

  192. 192.

    Hu, B. et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc. Natl Acad. Sci. USA 107, 21635–21640 (2010).

  193. 193.

    Siegmund, B., Lehr, H. A., Fantuzzi, G. & Dinarello, C. A. IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc. Natl Acad. Sci. USA 98, 13249–13254 (2001).

  194. 194.

    Bauer, C., Duewell, P., Lehr, H. A., Endres, S. & Schnurr, M. Protective and aggravating effects of Nlrp3 inflammasome activation in IBD models: influence of genetic and environmental factors. Dig. Dis. 30 (Suppl. 1), 82–90 (2012).

  195. 195.

    Youm, Y. H. et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 21, 263–269 (2015).

  196. 196.

    Yan, Y. et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 38, 1154–1163 (2013).

  197. 197.

    Maslowski, K. M. et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282–1286 (2009).

  198. 198.

    Macia, L. et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat. Commun. 6, 6734 (2015).

  199. 199.

    Du, Q. et al. Dietary cholesterol promotes AOM-induced colorectal cancer through activating the NLRP3 inflammasome. Biochem. Pharmacol. 105, 42–54 (2016).

  200. 200.

    Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12, 408–415 (2011).

  201. 201.

    Robblee, M. M. et al. Saturated fatty acids engage an IRE1alpha-dependent pathway to activate the NLRP3 inflammasome in myeloid cells. Cell Rep. 14, 2611–2623 (2016).

  202. 202.

    Progatzky, F. et al. Dietary cholesterol directly induces acute inflammasome-dependent intestinal inflammation. Nat. Commun. 5, 5864 (2014).

  203. 203.

    Zhao, S. et al. Deoxycholic acid triggers NLRP3 inflammasome activation and aggravates DSS-induced colitis in mice. Front. Immunol. 7, 536 (2016).

  204. 204.

    Williams, T. M. et al. The NLRP1 inflammasome attenuates colitis and colitis-associated tumorigenesis. J. Immunol. 194, 3369–3380 (2015).

  205. 205.

    Man, S. M. et al. Critical role for the DNA sensor AIM2 in stem cell proliferation and cancer. Cell 162, 45–58 (2015).

  206. 206.

    Wilson, J. E. et al. Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt. Nat. Med. 21, 906–913 (2015). References 205 and 206 identify a role for the DNA sensor AIM2 in preventing colorectal cancer in mice.

  207. 207.

    Hu, S. et al. The DNA Sensor AIM2 Maintains Intestinal homeostasis via regulation of epithelial antimicrobial host defense. Cell Rep. 13, 1922–1936 (2015).

  208. 208.

    Ratsimandresy, R. A., Indramohan, M., Dorfleutner, A. & Stehlik, C. The AIM2 inflammasome is a central regulator of intestinal homeostasis through the IL-18/IL-22/STAT3 pathway. Cell. Mol. Immunol. 14, 127–142 (2017).

  209. 209.

    Demon, D. et al. Caspase-11 is expressed in the colonic mucosa and protects against dextran sodium sulfate-induced colitis. Mucosal Immunol. 7, 1480–1491 (2014).

  210. 210.

    Williams, T. M. et al. Caspase-11 attenuates gastrointestinal inflammation and experimental colitis pathogenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 308, G139–G150 (2014).

  211. 211.

    Oficjalska, K. et al. Protective role for caspase-11 during acute experimental murine colitis. J. Immunol. 194, 1252–1260 (2014).

  212. 212.

    Takagi, H. et al. Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. Scand. J. Gastroenterol. 38, 837–844 (2003).

  213. 213.

    Salcedo, R. et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J. Exp. Med. 207, 1625–1636 (2010).

  214. 214.

    Otani, K. et al. Colchicine prevents NSAID-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Sci. Rep. 6, 32587 (2016).

  215. 215.

    Dupaul-Chicoine, J. et al. The Nlrp3 Inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity 43, 751–763 (2015).

  216. 216.

    Nowarski, R. et al. Epithelial IL-18 equilibrium controls barrier function in colitis. Cell 163, 1444–1456 (2015).

  217. 217.

    Ishikura, T. et al. Interleukin-18 overproduction exacerbates the development of colitis with markedly infiltrated macrophages in interleukin-18 transgenic mice. J. Gastroenterol. Hepatol. 18, 960–969 (2003).

  218. 218.

    Huber, S. et al. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491, 259–263 (2012).

  219. 219.

    Coll, R. C. et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 21, 248–255 (2015). This study reports a potent and selective inhibitor of the NLRP3 inflammasome and its use in multiple mouse models of inflammatory diseases.

  220. 220.

    Guo, W. et al. Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer. Autophagy 10, 972–985 (2014).

  221. 221.

    Jiang, H. et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J. Exp. Med. 214, 3219 (2017).

  222. 222.

    Romberg, N. et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat. Genet. 46, 1135–1139 (2014).

  223. 223.

    Canna, S. W. et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat. Genet. 46, 1140–1146 (2014).

  224. 224.

    Kitamura, A., Sasaki, Y., Abe, T., Kano, H. & Yasutomo, K. An inherited mutation in NLRC4 causes autoinflammation in human and mice. J. Exp. Med. 211, 2385–2396 (2014). References 222, 223 and 224 collectively report an association between mutations in NLRC4 and inflammatory conditions in humans. They also highlight the therapeutic relevance of inflammasome blockade in the treatment of these clinical manifestations.

  225. 225.

    Canna, S. W. et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J. Allergy Clin. Immunol. 139, 1698–1701 (2017).

  226. 226.

    Allam, R. et al. Epithelial NAIPs protect against colonic tumorigenesis. J. Exp. Med. 212, 369–383 (2015).

  227. 227.

    Garaude, J., Kent, A., van Rooijen, N. & Blander, J. M. Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci. Transl Med. 4, 120ra116 (2012).

  228. 228.

    Dihlmann, S. et al. Lack of Absent in Melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients. Int. J. Cancer 135, 2387–2396 (2014).

  229. 229.

    Karki et al. NLRC3 is an inhibitory sensor of PI3K–mTOR pathways in cancer. Nature 540, 583–587 (2016).

  230. 230.

    Man, S. M., Karki, R. & Kanneganti, T. D. AIM2 inflammasome in infection, cancer, and autoimmunity: role in DNA sensing, inflammation, and innate immunity. Eur. J. Immunol. 46, 269–280 (2016).

  231. 231.

    Hu, B. et al. The DNA-sensing AIM2 inflammasome controls radiation-induced cell death and tissue injury. Science 354, 765–768 (2016).

  232. 232.

    Lian, Q. et al. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Res. 27, 784–800 (2017).

  233. 233.

    Alexander, J. L. et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat. Rev. Gastroenterol. Hepatol. 14, 356–365 (2017).

  234. 234.

    Normand, S. et al. Nod-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc. Natl Acad. Sci. USA 108, 9601–9606 (2011).

  235. 235.

    Chen, G. Y., Liu, M., Wang, F., Bertin, J. & Nunez, G. A functional role for Nlrp6 in intestinal inflammation and tumorigenesis. J. Immunol. 186, 7187–7194 (2011).

  236. 236.

    Birchenough, G. M., Nystrom, E. E., Johansson, M. E. & Hansson, G. C. A sentinel goblet cell guards the colonic crypt by triggering Nlrp6-dependent Muc2 secretion. Science 352, 1535–1542 (2016).

  237. 237.

    Seregin, S. S. et al. NLRP6 function in inflammatory monocytes reduces susceptibility to chemically induced intestinal injury. Mucosal Immunol. 10, 434–445 (2017).

  238. 238.

    O’Keefe, S. J. Diet, microorganisms and their metabolites, and colon cancer. Nat. Rev. Gastroenterol. Hepatol. 13, 691–706 (2016).

  239. 239.

    Bergstrom, K. et al. Defective intestinal mucin-type O-glycosylation causes spontaneous colitis-associated cancer in mice. Gastroenterology 151, 152–164 (2016).

  240. 240.

    Powell, N., Walker, M. M. & Talley, N. J. The mucosal immune system: master regulator of bidirectional gut-brain communications. Nat. Rev. Gastroenterol. Hepatol. 14, 143–159 (2017).

  241. 241.

    Man, S. M., Karki, R. & Kanneganti, T. D. DNA-sensing inflammasomes: regulation of bacterial host defense and the gut microbiota. Pathog. Dis. 74, ftw028 (2016).

  242. 242.

    Hu, B. et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc. Natl Acad. Sci. USA 110, 9862–9867 (2013).

  243. 243.

    Seregin, S. S. et al. NLRP6 protects Il10−/− mice from colitis by limiting colonization of Akkermansia muciniphila. Cell Rep. 19, 733–745 (2017).

  244. 244.

    Chen, L. et al. NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth. Nat. Immunol. 18, 541–551 (2017).

  245. 245.

    Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179–185 (2012).

  246. 246.

    Mamantopoulos, M. et al. Nlrp6- and ASC-dependent inflammasomes do not shape the commensal gut microbiota composition. Immunity 47, 339–348 (2017).

  247. 247.

    Lemire, P. et al. The NLR protein NLRP6 does not impact gut microbiota composition. Cell Rep. 21, 3653–3661 (2017). References 246 and 247 demonstrate, using littermate-controlled experiments, that certain inflammasomes do not influence the composition of the gut microbiota in mice.

  248. 248.

    Levy, M. et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell 163, 1428–1443 (2015).

  249. 249.

    Sun, Y. et al. Stress-induced corticotropin-releasing hormone-mediated NLRP6 inflammasome inhibition and transmissible enteritis in mice. Gastroenterology 144, 1478–1487 (2013).

  250. 250.

    Pierantonelli, I. et al. Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD. Sci. Rep. 7, 12200 (2017).

  251. 251.

    Lukens, J. R. et al. Dietary modulation of the microbiome affects autoinflammatory disease. Nature 516, 246–249 (2014).

  252. 252.

    Rao, S. et al. Pathogen-mediated inhibition of anorexia promotes host survival and transmission. Cell 168, 503–516 (2017).

  253. 253.

    Wong, M. L. et al. Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition. Mol. Psychiatry 21, 797–805 (2016).

  254. 254.

    Lara-Tejero, M. et al. Role of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J. Exp. Med. 203, 1407–1412 (2006).

  255. 255.

    Song-Zhao, G. X. et al. Nlrp3 activation in the intestinal epithelium protects against a mucosal pathogen. Mucosal Immunol. 7, 763–774 (2014).

  256. 256.

    Allen, I. C. et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kappaB signaling. Immunity 36, 742–754 (2012).

  257. 257.

    Zaki, M. H. et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell 20, 649–660 (2011). References 256 and 257 reveal an important role for NLRP12 in colitis and colitis-associated colorectal cancer in mice.

Download references


S.M.M. is supported by the Australian National University Futures Award, The Gretel and Gordon Bootes Medical Research Foundation and the National Health and Medical Research Council of Australia under project grants (APP1141504 and APP1146864) and the R.G. Menzies Early Career Fellowship (APP1091544). The author apologizes to researchers whose work was not cited or was cited through reviews owing to space limitations.

Reviewer information

Nature Reviews Gastroenterology & Hepatology thanks R. Flavell, T. Monie and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Review criteria

A detailed literature review was performed using the PubMed database using a combination of the following search terms: “inflammasome”, “NLRP1”, “NLRP3”, “NLRC4”, “AIM2”, “pyrin”, “caspase-1”, “caspase-4”, “caspase-5”, “caspase-11”, “pyroptosis”, “IL-1”, “IL-18”, “infection”, “bacteria”, “viruses”, “protozoa”, “colitis”, “IBD”, “cancer” and “microbiota”. Relevant English-language papers were evaluated.

Author information


  1. Department of Immunology and Infectious Disease, The John Curtin School of Medical Research, The Australian National University, Canberra, Australia

    • Si Ming Man


  1. Search for Si Ming Man in:

Competing interests

The author declares no competing interests.

Corresponding author

Correspondence to Si Ming Man.

Supplementary information

About this article

Publication history